Form 4: Sana Biotechnology Officer Exercises Stock Options, Disposes of Shares to Cover Tax Obligations
SEC Form 4 Filing
Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, exercised stock options and disposed of shares to cover tax obligations on January 2, 2025.
Summary
- On January 2, 2025, Susan D. Wyrick, Acting Chief Financial Officer and Principal Accounting Officer of Sana Biotechnology, Inc., exercised restricted stock units to acquire 5,000 shares of common stock.
- Wyrick also disposed of 1,566 shares of common stock at a price of $1.65 to satisfy tax withholding obligations.
- Following these transactions, Wyrick directly owns 153,946 shares of Sana Biotechnology common stock and 7,500 restricted stock units.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider transactions, with no inherent positive or negative implications for the company's overall performance or outlook.
Future Outlook
The remaining 60% of the restricted stock units will vest on January 2, 2026, provided that the reporting person provides continuous service to Sana.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company officers and their holdings in the company's stock.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies in the US, as mandated by the SEC.
- The vesting schedule of the restricted stock units (40% on January 2, 2025, and 60% on January 2, 2026) is a typical arrangement for employee equity compensation.
- The disposal of shares to cover tax obligations is a common occurrence when employees exercise stock options or restricted stock units.
Stakeholder Impact
- The transactions have a minimal impact on shareholders, as they represent a small percentage of the total outstanding shares.
- The vesting of restricted stock units incentivizes the officer to remain with the company.
Key Dates
| Date | Description |
|---|---|
| 11/15/2024 | 3,000 shares acquired on November 15, 2024 pursuant to Sana Biotechnology, Inc.'s ('Sana') 2021 Employee Stock Purchase Plan. |
| 01/02/2025 | Date of earliest transaction: Exercise of restricted stock units and disposal of shares for tax obligations. |
| 01/02/2025 | 40% of the restricted stock units vested. |
| 01/02/2026 | Remaining 60% of the restricted stock units will vest, contingent upon continued service. |
| 01/03/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.